• 1
    Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-226.
  • 2
    Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 2011;89:788-790.
  • 3
    Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715.
  • 4
    Soars MG, McGinnity DF, Grime K, Riley RJ. The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 2007;168:2-15.
  • 5
    Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2006;2:183-212.
  • 6
    Huang P, He Z, Ji S, Sun H, Xiang D, Liu C, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011;475:386-389.
  • 7
    Baxter MA, Rowe C, Alder J, Harrison S, Hanley KP, Park BK, et al. Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res 2010;5:4-22.
  • 8
    Kia R, Sison RL, Heslop J, Kitteringham NR, Hanley N, Mills JS, et al. Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol 2013;75:885-896.
  • 9
    Sison-Young RL, Kia R, Heslop J, Kelly L, Rowe C, Cross MJ, et al. Human pluripotent stem cells for modeling toxicity. Adv Pharmacol 2012;63:207-256.
  • 10
    Elaut G, Henkens T, Papeleu P, Snykers S, Vinken M, Vanhaecke T, et al. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 2006;7:629-660.
  • 11
    Lee SJ, Friedman SL, Whalen R, Boyer TD. Cellular sources of glutathione S-transferase P in primary cultured rat hepatocytes: localization by in situ hybridization. Biochem J 1994;299:79-83.
  • 12
    Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN, McCarver DG. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 2003;307:402-407.
  • 13
    Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004;308:965-974.
  • 14
    Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002;300:355-360.
  • 15
    Maruyama M, Matsunaga T, Harada E, Ohmori S. Comparison of basal gene expression and induction of CYP3As in HepG2 and human fetal liver cells. Biol Pharm Bull 2007;30:2091-2097.
  • 16
    Yu Y, Zhang C, Zhou G, Wu S, Qu X, Wei H, et al. Gene expression profiling in human fetal liver and identification of tissue- and developmental-stage-specific genes through compiled expression profiles and efficient cloning of full-length cDNAs. Genome Res 2001;11:1392-1403.
  • 17
    Ying W, Jiang Y, Guo L, Hao Y, Zhang Y, Wu S, et al. A dataset of human fetal liver proteome identified by subcellular fractionation and multiple protein separation and identification technology. Mol Cell Proteomics 2006;5:1703-1707.
  • 18
    Moghe PV, Berthiaume F, Ezzell RM, Toner M, Tompkins RG, Yarmush ML. Culture matrix configuration and composition in the maintenance of hepatocyte polarity and function. Biomaterials 1996;17:373-385.
  • 19
    Brophy CM, Luebke-Wheeler JL, Amiot BP, Khan H, Remmel RP, Rinaldo P, et al. Rat hepatocyte spheroids formed by rocked technique maintain differentiated hepatocyte gene expression and function. Hepatology 2009;49:578-586.
  • 20
    Tostoes R, Leite SB, Serra M, Jensen J, Bjorquist P, Carrondo M, et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeated dose drug testing. Hepatology 2012;55:1227-1236.
  • 21
    Brandenburger M, Wenzel J, Bogdan R, Richardt D, Nguemo F, Reppel M, et al. Organotypic slice culture from human adult ventricular myocardium. Cardiovasc Res 2012;93:50-59.
  • 22
    Gauvin R, Larouche D, Marcoux H, Guignard R, Auger FA, Germain L, et al. Minimal contraction for tissue-engineered skin substitutes when matured at the air-liquid interface. J Tissue Eng Regen Med 2012;2012:943982.
  • 23
    Hanley KP, Oakley F, Sugden S, Wilson DI, Mann DA, Hanley NA. Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis. J Biol Chem 2008;283:14063-14071.
  • 24
    Carpentier R, Suner RE, Van Hul N, Kopp JL, Beaudry JB, Cordi S, et al. Embryonic ductal plate cells give rise to cholangiocytes, periportal hepatocytes and adult liver progenitor cells. Gastroenterology 2011;141:1432-1438.
  • 25
    Furuyama K, Kawaguchi Y, Akiyama H, Horiguchi M, Kodama S, Kuhara T, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet 2011;43:34-41.
  • 26
    Raynaud P, Tate J, Callens C, Cordi S, Vandersmissen P, Carpentier R, et al. A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Hepatology 2011;53:1959-1966.
  • 27
    Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 2012;27:55-67.
  • 28
    Melton AC, Yee HF. Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis. Hepatology 2007;45:1446-1453.
  • 29
    Consortium CHLPP. First insight into the human liver proteome from PROTEOME(SKY)-LIVER(Hu) 1.0, a publicly available database. J Proteome Res 2010;9:79-94.
  • 30
    Eastman QM. Mammoth data set from human liver reported. J Proteome Res 2010;9:3.
  • 31
    Zhou C, Simpson K, Lancashire LJ, Walker MJ, Dawson MJ, Unwin RD, et al. Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery. J Proteome Res 2012;291:56-64.
  • 32
    Pan C, Kumar C, Bohl S, Klingmueller U, Mann M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics 2009;8:443-450.
  • 33
    Rowe C, Goldring CE, Kitteringham NR, Jenkins RE, Lane BS, Sanderson C, et al. Network analysis of primary hepatocyte dedifferentiation using a shotgun proteomics approach. J Proteome Res 2010;9:2658-2668.
  • 34
    Van Summeren A, Renes J, Bouwman FG, Noben JP, van Delft JH, Kleinjans JC, et al. Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci 2011;120:109-122.
  • 35
    Slany A, Haudek VJ, Zwickl H, Gundacker NC, Grusch M, Weiss TS, et al. Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res 2010;9:6-21.
  • 36
    Hay DC, Zhao D, Fletcher J, Hewitt ZA, McLean D, Urruticoechea-Uriguen A, et al. Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells 2008;26:894-902.
  • 37
    Pikkarainen PH, Raiha NC. Development of alcohol dehydrogenase activity in the human liver. Pediatr Res 1967;1:165-168.
  • 38
    Stewart MJ, Shean ML, Paeper BW, Duester G. The role of CCAAT/enhancer-binding protein in the differential transcriptional regulation of a family of human liver alcohol dehydrogenase genes. J Biol Chem 1991;266:11594-11603.
  • 39
    Pitarque M, Rodriguez-Antona C, Oscarson M, Ingelman-Sundberg M. Transcriptional regulation of the human CYP2A6 gene. J Pharmacol Exp Ther 2005;313:814-822.
  • 40
    Sakai M, Muramatsu M. Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis. Biochem Biophys Res Commun 2007;357:575-578.
  • 41
    Pochareddy S, Edenberg HJ. Identification of a FOXA-dependent enhancer of human alcohol dehydrogenase 4 (ADH4). Gene 2010;460:1-7.
  • 42
    Masaki T, Tokuda M, Yoshida S, Nakai S, Morishita A, Uchida N, et al. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol 2005;26:661-671.
  • 43
    Garibaldi F, Cicchini C, Conigliaro A, Santangelo L, Cozzolino AM, Grassi G, et al. An epistatic mini-circuitry between the transcription factors Snail and HNF4alpha controls liver stem cell and hepatocyte features exhorting opposite regulation on stemness-inhibiting microRNAs. Cell Death Differ 2012;19:937-946.
  • 44
    Santangelo L, Marchetti A, Cicchini C, Conigliaro A, Conti B, Mancone C, et al. The stable repression of mesenchymal program is required for hepatocyte identity: a novel role for hepatocyte nuclear factor 4alpha. Hepatology 2011;53:2063-2074.